First Allied Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

First Allied Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-1,900	Closed	-$523K	–	196
2013 Q4	$523K	Hold	1,900	–	–	0.08%	147
2013 Q3	$594K	Hold	1,900	–	–	0.09%	131
2013 Q2	$427K	Buy	+1,900	New	+$442K	0.06%	162

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

First Allied Asset Management's REGN Position: Q1 2014 in Review

First Allied Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2014, closing a stake of 1,900 shares — an estimated $523K sold.

First Allied Asset Management first reported a position in REGN in Q2 2013 and held it in 3 quarters. The position peaked at $594K in Q3 2013. 453 funds tracked by Wall St. Rank hold REGN as of Q1 2014.

First Allied Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
First Allied Asset Management sold 1,900 Regeneron Pharmaceuticals shares in Q1 2014, an estimated $523K.
First Allied Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 3 quarters.
First Allied Asset Management's Regeneron Pharmaceuticals position peaked at $594K in Q3 2013.
453 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2014.

Based on First Allied Asset Management's 13F filing for Q1 2014, filed 14 May 2014.